| Literature DB >> 21524316 |
Miguel A Salinero-Fort1, Enrique Carrillo-de Santa Pau, Francisco J Arrieta-Blanco, Juan C Abanades-Herranz, Carmen Martín-Madrazo, Berta Rodés-Soldevila, Carmen de Burgos-Lunar.
Abstract
BACKGROUND: Individual health education is considered to be essential in the overall care of patients with type 2 diabetes (DM2), although there is some uncertainty regarding its metabolic control benefits. There have been very few randomized studies on the effects of individual education on normal care in DM2 patients with a control group, and none of these have assessed the long-term results. Therefore, this study aims to use this design to assess the effectiveness of the PRECEDE (Predisposing, Reinforcing, Enabling, Causes in Educational Diagnosis, and Evaluation) education model in the metabolic control and the reduction of cardiovascular risk factors, in patients with type 2 diabetes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21524316 PMCID: PMC3098792 DOI: 10.1186/1471-2458-11-267
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Flow Diagram of participants. HPE: Health Promotion Education.
Figure 2Contents of the PRECEDE health promotion education model.
Baseline characteristics of participants by HPE Assignment.
| PRECEDE | CONTROL | ||
|---|---|---|---|
| 53.8 (50.6-57) | 49.3 (46.1-52.5) | 0.27 | |
| 66.06 (8) | 67.28 (19) | 0.3 | |
| 8.80 (8) | 9.49 (8) | 0.29 | |
| 9.5 (6.3-12.7) | 15.1 (4.6-25.6) | 0.36 | |
| 11.88 (10) | 12.36 (9) | 0.84 | |
| 3.11 (8) | 5.08 (30) | 0.27 | |
| 7.55 (4) | 7.98 (5) | 0.25 | |
| 67.9 (62.8-73) | 64.2 (58.8-69.6) | 0.33 | |
| 65.7 (60.5-70.9) | 93.6 (90.8-96.4) | <0.01 | |
| 55.7 (50.2-61.2) | 74.2 (69.3-79.2) | <0.01 | |
| 81.3 (77-85.6) | 93.9 (91.2-96.6) | <0.01 | |
| Diet | 79.5 (75.1-83.9) | 72.8 (67.8-77.8) | 0.05 |
| Sulfonylureas | 42.3 (36.9-47.7) | 44.5 (38.9-50.1) | 0.58 |
| Meglitinide | 4.1 (1.9-6.3) | 1.3 (0-2.6) | 0.03 |
| Biguanides | 25.6 (20.8-30.4) | 19.7 (15.2-24.2) | 0.08 |
| Thiazolidinediones | 0.3 (0.3-0.9) | 1 (0-2.1) | 0.29 |
| Alpha glucosidase inhibitors | 11 (7.6-14.4) | 9 (5.8-12.2) | 0.41 |
| Insulin | 14.2 (10.4-18) | 14.4 (10.4-18.4) | 0.94 |
| Diuretics | 27.4 (22.5-32.3) | 23.1 (18.3-27.9) | 0.23 |
| Beta blockers | 12.9 (9.2-16.6) | 9.7 (6.4-13.1) | 0.22 |
| ACE inhibitors | 30.6 (25.5-35.7) | 29.1 (24-34.2) | 0.68 |
| ARB | 14.5 (10.6-18.4) | 12.4 (8.7-16.1) | 0.47 |
| Hypolipidemic | 35.3 (30.1-40.6) | 30.4 (25.2-35.6) | 0.2 |
| Calcium antagonist | 15.1% (11.2-19) | 19.1 (14.7-23.6) | 0.19 |
| Antiplatelet | 22.4 (17.8-27) | 17.7 (13.4-22) | 0.15 |
| Anticoagulants | 3.2 (1.3-5.1) | 3.7 (1.6-5.8) | 0.74 |
| Hypertension | 69.7 (64.6-74.7) | 63.5 (58.1-69) | 0.1 |
| Dyslipidemia | 48.7 (43.2-54.2) | 44.8 (39.2-50.4) | 0.33 |
| CHD Angina | 12.9 (9.2-16.6) | 7 (4.1-9.9) | 0.01 |
| AMI | 9.1 (5.9-12.3) | 7 (4.1-9.9) | 0.34 |
| Stroke | 3.2 (1.3-5.1) | 6 (3.3-8.7) | 0.1 |
| Retinopathy | 10.5 (7.1-13.9) | 6.5 (3.7-9.3) | 0.08 |
| Nephropathy | 5 (2.6-7.4) | 4.1 (1.9-6.3) | 0.6 |
| Neuropathy | 6 (3.4-8.6) | 2.4 (0.7-4.1) | 0.03 |
| Total Cholesterol (mg/dl) | 203 (33) | 205 (33) | 0.45 |
| HDL Cholesterol (mg/dl) | 51 (14) | 47 (11) | <0.01 |
| LDL Cholesterol (mg/dl) | 125 (29) | 129 (28) | 0.09 |
| Triglycerides (mg/dl) | 134 (70) | 133 (76) | 0.87 |
| HbA1c (%) | 7.05 (1.3) | 7.36 (1.2) | <0.01 |
| Body Mass Index (Kg/m2) | 29.58 (4.58) | 30.54 (5.16) | 0.02 |
| Systolic Blood Pressure (mmHg) | 137 (165 | 134 (15) | 0.02 |
| Diastolic Blood Pressure (mmHg) | 80 (8) | 77 (8) | <0.01 |
Values are given as mean (SD) unless otherwise specified.
CI: Confidence Interval; ACE: Inhibitors of angiotensin converting enzyme; ARB: Inhibitors of the Renin Angiotensin II receptor; CHD: Coronary Heart Disease; AMI: Acute myocardial infarction.
Mean values (SD) and changes of basal and final parameters in both groups.
| PRECEDE | CONTROL | Unadjusted PRECEDE effect | Adjusted PRECEDE effect | |
|---|---|---|---|---|
| Basal | 203 (33) | 205 (33) | ||
| Final | 194 (34) | 194 (33) | ||
| Change | -9.36 (33) | -10.88 (31) | 1.51 (-3.6 to 6.6) | -0.10 (-4.8 to 4.56) |
| 0.67 | 0.88 | 0.56 | 0.97 | |
| Basal | 125 (29) | 129 (28) | ||
| Final | 118 (30) | 122 (28) | ||
| Change | -7.25 (30) | -7.27 (28) | 0.02 (-4.6 to 4.7) | -2.64 (-6.9 to 1.6) |
| 0.1 | 0.11 | 0.99 | 0.22 | |
| Basal | 51 (14) | 47 (11) | ||
| Final | 52 (14) | 51 (14) | ||
| Change | 0.8 (13) | 3.7 (8) | -2.87 (-1.1 to -4.6) | -1.70 (-3.3 to -0.1) |
| <0.01 | 0.51 | <0.01 | 0.03 | |
| Basal | 7.05 (1.3) | 7.36 (1.2) | ||
| Final | 7.02 (1.2) | 7.38 (1.1) | ||
| Change | -0.03 (0.9) | 0.04 (1) | -0.07 (0.2 to 0.1) | -0.18 (-0.3 to -0.04) |
| <0.01 | <0.01 | 0.40 | 0.01 | |
| Basal | 137 (15) | 134 (15) | ||
| Final | 133 (13) | 135 (16) | ||
| Change | -4.22 (14) | 0.18 (16) | -4.40 (-2 to -6.8) | -3.09 (-1.1 to -5.1) |
| 0.05 | 0.08 | <0.01 | <0.01 | |
| Basal | 80 (8) | 77 (8) | ||
| Final | 77 (8) | 76 (8.7) | ||
| Change | -2.76 (8.9) | -0.75 (8.9) | -2.01 (-0.6 to 3.4) | -0.64 (-1.9 to 0.6) |
| <0.01 | 0.27 | 0.40 | 0.32 | |
| Basal | 29,63 (4,50) | 30,54 (5,16) | ||
| Final | 29,58 (4,58) | 30,43 (5,19) | ||
| Change | -0,05 (1,53) | -0,11 (1,58) | 0,06 (0,30 a -0,19) | -0,03 (-0,29 a 0,24) |
| 0,56 | 0,24 | 0,64 | 0,85 | |
HbA1C: Glycated hemoglobin; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body Mass Index.
Percentage of Subjects On-Target for Cardiovascular Risk Factors at Baseline and at the End of the 24-Month Study Period, stratified by HPE.
| Target | HPE | Baseline (%) | 24 Months (%) | Change (%) | ||
|---|---|---|---|---|---|---|
| Control | 40.7 | 39 | 0.61 | -1.7 | <0.01 | |
| Control | 15.7 | 22 | 0.02 | +6.3 | 0.55 | |
| Control | 5.7 | 9 | 0.06 | +3.3 | 0.02 | |
| Control | 12.7 | 12.5 | 0.90 | -0.2 | 0.85 | |
| Control | 28.7 | 29.3 | 0.91 | +0.6 | 0.02 | |
| Control | 49 | 52.7 | 0.32 | +3.7 | 0.01 | |
| Control | 21.3 | 21.7 | 1 | +0.4 | <0.01 | |
| Control | 0.7 | 1 | 1 | +0.3 | 0.02 | |
1. HbA1c <7% and LDL cholesterol <100 mg/dl.
2. SBP <130 mmHg and DBP <80 mmHg.
3. Metabolic control and BP control.
HPE: Health Promotion Education; SBP: Systolic blood pressure; BMI: Body Mass Index; DBP: Diastolic blood pressure; BP: Blood pressure; HbA1C: Glycated hemoglobin.